Actylis Biopharma Capabilities Video

The new building expands on the company’s supply chain solutions for biologics and temperature-sensitive pharmaceuticals.

In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.

The company’s mocravimod, a novel oral S1P receptor, is being evaluated for its efficacy as an addition to CAR-T cell therapies.

As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.

The 12th edition of the European Pharmacopoeia will be an all-digital, redesigned, user-friendly issue.

As molecules grow more complex, drug developers in the pharma landscape face an increasing number of challenges in formulation, manufacturability, and sustainability. Fortunately, novel formulation strategies and technologies are reshaping drug development, from overcoming oral solid dose (OSD) challenges to advancing bioavailability and redefining traditional drug-likeness criteria.